A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal

A prospective, randomised, double-blind, lacebo-controlled trial

Nicholas N. Tadros, Lisa Bland, Edith Legg, Ali Olyaei, Michael Conlin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives: To determine the incidence of severe pain after ureteric stent removal. To evaluate the efficacy of a single dose of a non-steroidal anti-inflammatory drug (NSAID) in preventing this complication. Patients and Methods: A prospective, randomised, double-blind, placebo-controlled trial was performed at our institution. Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal. Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal Pain medication use after ureteric stent removal was measured using morphine equivalents. Results: In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed significant decrease in pain level in the NSAID group. The most common indication for ureteroscopy was urolithiasis (14 patients). The proportion of patients with severe pain (VAS score of ≥7) during the 24 h after ureteric stent removal was six of 11 (55%) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01). There were no complications related to the use of rofecoxib. Conclusions: We found a 55% incidence of severe pain after ureteric stent removal. A single dose of a NSAID before stent removal prevents severe pain after ureteric stent removal.

Original languageEnglish (US)
Pages (from-to)101-105
Number of pages5
JournalBJU International
Volume111
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Stents
Anti-Inflammatory Agents
Pain
Pharmaceutical Preparations
Ureteroscopy
Placebos
Urolithiasis
Incidence
Pain Measurement
Visual Analog Scale
Morphine

Keywords

  • NSAIDs
  • stents
  • ureteroscopy
  • urolithiasis

ASJC Scopus subject areas

  • Urology

Cite this

A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal : A prospective, randomised, double-blind, lacebo-controlled trial. / Tadros, Nicholas N.; Bland, Lisa; Legg, Edith; Olyaei, Ali; Conlin, Michael.

In: BJU International, Vol. 111, No. 1, 01.01.2013, p. 101-105.

Research output: Contribution to journalArticle

@article{30eec5c8ebcc4d2abc93cde1e70d002b,
title = "A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: A prospective, randomised, double-blind, lacebo-controlled trial",
abstract = "Objectives: To determine the incidence of severe pain after ureteric stent removal. To evaluate the efficacy of a single dose of a non-steroidal anti-inflammatory drug (NSAID) in preventing this complication. Patients and Methods: A prospective, randomised, double-blind, placebo-controlled trial was performed at our institution. Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal. Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal Pain medication use after ureteric stent removal was measured using morphine equivalents. Results: In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed significant decrease in pain level in the NSAID group. The most common indication for ureteroscopy was urolithiasis (14 patients). The proportion of patients with severe pain (VAS score of ≥7) during the 24 h after ureteric stent removal was six of 11 (55{\%}) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01). There were no complications related to the use of rofecoxib. Conclusions: We found a 55{\%} incidence of severe pain after ureteric stent removal. A single dose of a NSAID before stent removal prevents severe pain after ureteric stent removal.",
keywords = "NSAIDs, stents, ureteroscopy, urolithiasis",
author = "Tadros, {Nicholas N.} and Lisa Bland and Edith Legg and Ali Olyaei and Michael Conlin",
year = "2013",
month = "1",
day = "1",
doi = "10.1111/j.1464-410X.2012.11214.x",
language = "English (US)",
volume = "111",
pages = "101--105",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal

T2 - A prospective, randomised, double-blind, lacebo-controlled trial

AU - Tadros, Nicholas N.

AU - Bland, Lisa

AU - Legg, Edith

AU - Olyaei, Ali

AU - Conlin, Michael

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objectives: To determine the incidence of severe pain after ureteric stent removal. To evaluate the efficacy of a single dose of a non-steroidal anti-inflammatory drug (NSAID) in preventing this complication. Patients and Methods: A prospective, randomised, double-blind, placebo-controlled trial was performed at our institution. Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal. Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal Pain medication use after ureteric stent removal was measured using morphine equivalents. Results: In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed significant decrease in pain level in the NSAID group. The most common indication for ureteroscopy was urolithiasis (14 patients). The proportion of patients with severe pain (VAS score of ≥7) during the 24 h after ureteric stent removal was six of 11 (55%) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01). There were no complications related to the use of rofecoxib. Conclusions: We found a 55% incidence of severe pain after ureteric stent removal. A single dose of a NSAID before stent removal prevents severe pain after ureteric stent removal.

AB - Objectives: To determine the incidence of severe pain after ureteric stent removal. To evaluate the efficacy of a single dose of a non-steroidal anti-inflammatory drug (NSAID) in preventing this complication. Patients and Methods: A prospective, randomised, double-blind, placebo-controlled trial was performed at our institution. Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal. Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal Pain medication use after ureteric stent removal was measured using morphine equivalents. Results: In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed significant decrease in pain level in the NSAID group. The most common indication for ureteroscopy was urolithiasis (14 patients). The proportion of patients with severe pain (VAS score of ≥7) during the 24 h after ureteric stent removal was six of 11 (55%) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01). There were no complications related to the use of rofecoxib. Conclusions: We found a 55% incidence of severe pain after ureteric stent removal. A single dose of a NSAID before stent removal prevents severe pain after ureteric stent removal.

KW - NSAIDs

KW - stents

KW - ureteroscopy

KW - urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=84871592912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871592912&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11214.x

DO - 10.1111/j.1464-410X.2012.11214.x

M3 - Article

VL - 111

SP - 101

EP - 105

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -